CJC-1295 is an artificially synthesized peptide hormone, belonging to the analog of growth hormone-releasing hormone (GHRH). Since it was first included in the "Doping List" in 2019, its regulatory scope has continuously expanded. In the 2023 version, it is clearly labeled as "growth hormone stimulating agent (GHS)" and is particularly emphasized as prohibited for male athletes. This substance activates the pituitary growth hormone release receptor, promoting the secretion of endogenous growth hormone (GH) and insulin-like growth factor-1 (IGF-1), demonstrating unique value in metabolic regulation, muscle growth, and fat breakdown.
|
|
|
|
|
|
|
|
Chemical Nature and Mechanism of Action
CJC-1295 is composed of 30 amino acids. Its molecular structure is highly similar to the natural GHRH, but through chemical modification, it achieves a significant extension of its half-life. The half-life of the original GHRH is only a few minutes, while CJC-1295, by adding a drug affinity complex (DAC), binds to albumin in the blood, extending its half-life to 6-8 days. This long-lasting characteristic makes it one of the longest-lasting GHRH analogues currently available on the market.
Its mechanism of action is based on the specific activation of the anterior pituitary GHRH receptor. After a single injection of 2mg CJC-1295, the plasma GH level can increase by 2-10 times within 6 days, and the IGF-1 level can increase by 0.5-3 times within 9-11 days. After multiple administrations, the IGF-1 level can remain elevated for up to 28 days. Unlike the direct use of synthetic growth hormone, CJC-1295 stimulates endogenous secretion, avoiding the inhibition of its own secretion function by exogenous hormones.
Physiological Effects and Clinical Applications
Metabolic Regulation
CJC-1295 significantly enhances fat oxidation and energy metabolism by increasing GH and IGF-1 levels. Clinical studies show that after 6 days of use, the body fat percentage of the subjects decreased by an average of 2.3%, and the basal metabolic rate increased by 15%. This effect is particularly evident during the slow-wave sleep period at night, which is highly synchronized with the circadian rhythm of GH secretion.
Muscle Growth and Repair
In subjects aged 21-61, continuous use of CJC-1295 can increase lean body mass by 3.2 kg and expand muscle cross-sectional area by 12%. The mechanism involves the activation of satellite cells by IGF-1, promoting myofibril protein synthesis. Among athletes, this substance is often combined with Iparalin (GHRP) to form a "pulse-persistent" GH secretion pattern, further enhancing anabolic effects.
Performance Enhancement
For strength athletes, using CJC-1295 results in an average increase of 18% in squat maximum strength and a 2.3-second shortening of 800-meter running performance. This performance improvement is due to increased muscle glycogen reserves and accelerated lactate clearance rate. Among endurance and strength athletes, its usage rate reached 12% in 2024, but attention should be paid to the risk of anti-doping regulation.
Differences in Formulations and Usage Schemes
DAC and Non-DAC Versions
CJC-1295 + DAC: Half-life 8 days, 1-2 injections per week, suitable for long-term metabolic regulation.
CJC-1295 without DAC (i.e., MOD GRF 1-29): Half-life 30 minutes, requires 1-3 injections per day, simulating the physiological GH pulse secretion.
The two formulations have comparable effects in promoting IGF-1 secretion, but the DAC version is more favored by athletes due to its lower injection frequency.
Typical Medication Schemes
Growth Phase: 2 injections per week of 2 mg CJC-1295 + DAC, combined with 3 daily injections of 100 mcg Iparalin.
Losing Fat Phase: 1 injection per week of 2 mg CJC-1295 + DAC, combined with 2 daily injections of 200 mcg Tesomorin.
Hormone Recovery: 1-month "hormone break" every 3 months to avoid pituitary function inhibition.
Regulatory Framework and Legal Risks
International Regulatory Framework
CJC-1295 is classified as S2 peptide hormone by the World Anti-Doping Agency (WADA). In 2023, it was classified as "growth hormone secretion stimulator" in the "Doping List", and is explicitly prohibited for athletes. Customs implements full-chain monitoring through special codes (2937190013 raw materials, 3004390025 preparations), and import and export require providing "Import Permit" and "Export Permit".
Legal Liability
In China, illegal production and sale of CJC-1295 can violate Article 141 of the Criminal Law (production and sale of counterfeit drugs), with a maximum penalty of life imprisonment. In 2024, a certain biological company in Hangzhou was sentenced to a fine of 5 million yuan for illegal export, and the person in charge was sentenced to 8 years in prison.
Side Effects and Risk Management
Common Adverse Reactions
Acute Phase: Injection site redness (12% occurrence rate), headache (8%), flushing (5%).
Long-term Use: Decreased insulin sensitivity (blood sugar increase of 3-5 mg/dL), joint pain (7%), carpal tunnel syndrome (2%).
Special Risks: Male breast development (related to prolactin level fluctuations), aggravated sleep apnea.
Contraindications and Precautions
Absolute Contraindications: Pregnancy, active tumors, uncontrolled diabetes.
Relative Contraindications: Sleep apnea syndrome, prostate hypertrophy.
Monitoring Indicators: Every 3 months, test IGF-1 level, fasting blood sugar, thyroid function.
Research Frontiers and Future Directions
Anti-Aging Field
Animal experiments have shown that CJC-1295 can extend the lifespan of aged mice by 18% and slow down the rate of muscle atrophy by 40%. The human trial to be launched in 2025 will explore its improvement effect on senile sarcopenia.
Application in wound repair
In burn patients, the combined use of CJC-1295 and eprarin can shorten the wound healing time by 30% and reduce the scar area by 25%. The mechanism involves the activation of fibroblasts by IGF-1 and the promotion of collagen synthesis.
New delivery system
The development of nanoparticle encapsulation technology and transdermal patches aims to solve the issue of injection compliance. The micro-needle array patch to be announced in 2024 can increase the bioavailability of CJC-1295 to 45% and reduce pain by 80%.
Market Status and Purchase Guidelines
Price system
Research-grade raw materials: The price of 1g is approximately 3,000-5,000 yuan (purity ≥ 98%).
Formulation products: The price of 2mg per bottle is 800-1,500 yuan. They need to be obtained through special channels.
Counterfeit identification: The regular product should be labeled with CAS number 863288-34-0, providing HPLC chromatogram and COA certificate.
Supplier selection
The main domestic suppliers include Xi'an Vixen Biotechnology, Wuhan Bellka, etc., all of which have passed ISO 9001 certification. Imported products need to confirm the original factory authorization of Cayman Chemical, etc., to avoid purchasing smuggled sources from Southeast Asia.
Ethical Controversies and Social Impact
Fairness in competitive sports
In the 2024 Tour de France, three teams were exposed for using CJC-1295, resulting in the disqualification of the champion's result. This incident triggered discussions on "biohack" technology, and WADA is developing a saliva-based detection technology based on mass spectrometry, which can extend the detection window to 14 days.
Abuse in the beauty industry
Some medical beauty institutions package CJC-1295 as "youth peptide", with a single injection cost as high as 5,000 yuan. The National Health Commission has clearly listed it as a prohibited drug in medical beauty, and the illegal use can be punished by revoking the practice qualification.
As a milestone substance in the field of growth hormone regulation, CJC-1295 has both scientific value and regulatory challenges. Under the premise of strictly abiding by laws and regulations, reasonable exploration of its potential in metabolic disease treatment and sports medicine will be the core direction of future research. For the general population, healthy lifestyle intervention remains the preferred solution for improving metabolism. The use of any hormone drugs should be carried out under the guidance of a professional doctor.